Inpharma Weekly

, Volume 1636, Issue 1, pp 2–2 | Cite as

Sevelamer could be worth it in hyperphosphataemia

Clinical study
  • 4 Downloads

Keywords

Economic Evaluation Time Horizon Current Medical Dominant Strategy Absolute Threshold 

Copyright information

© Adis International Ltd 2008

Personalised recommendations